研究单位：[1]Bio-Thera Solutions[2]Tongji Hospital of Tongji Medical College of HUST Wuhan, Hubei, China[3]Hubei Cancer Hospital Wuhan, Hubei, China[4]Zhongnan Hospital of Wuhan University Wuhan, Hubei, China[5]Yichang Central Hospital Yichang, Hubei, China[6]Hunan Cancer Hospital Changsha, Hunan, China[7]Xiangya Hospital Central South University Changsha, Hunan, China[8]Jiangsu Cancer Hospital Nanning, Jiangsu, China[9]Affiliated Hospital of Jiangnan University Wuxi, Jiangsu, China[10]Yancheng City No. 1 People's Hospital Yancheng, Jiangsu, China[11]Jiangxi Cancer Hospital Nanchang, Jiangxi, China[12]The Third Hospital of Nanchang Nanchang, Jiangxi, China[13]Jilin Cancer Hospital Chang chun, Jilin, China[14]The First Bethune Hospital of Jilin University Changchun, Jilin, China[15]Jinzhou Central Hospital Jinzhou, Liaoning, China[16]Liaoning Cancer Hospital Shenyang, Liaoning, China[17]General Hospital of Ningxia Medical University Yinchuan, Ningxia, China[18]Shandong Cancer Hospital Jinan, Shandong, China[19]Linyi Cancer Hospital Linyi, Shandong, China[20]Weifang People's Hospital Weifang, Shandong, China[21]Fudan University Shanghai Cancer Hospital Shanghai, Shanghai, China
研究目的：
To evaluate the safety and efficacy of BAT8001 for the treatment of HER2-positive advanced breast cancer, using lapatinib in combination with capecitabine as the positive control drug.
